133 related articles for article (PubMed ID: 22236082)
1. Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide-based enzyme capture assay.
Müller J; Friedrich M; Becher T; Braunstein J; Kupper T; Berdel P; Gravius S; Rohrbach F; Oldenburg J; Mayer G; Pötzsch B
J Thromb Haemost; 2012 Mar; 10(3):390-8. PubMed ID: 22236082
[TBL] [Abstract][Full Text] [Related]
2. An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor.
Müller J; Isermann B; Dücker C; Salehi M; Meyer M; Friedrich M; Madhusudhan T; Oldenburg J; Mayer G; Pötzsch B
Chem Biol; 2009 Apr; 16(4):442-51. PubMed ID: 19389630
[TBL] [Abstract][Full Text] [Related]
3. The evolution of activated protein C plasma levels in septic shock and its association with mortality: A prospective observational study.
Becher T; Müller J; Akin I; Baumann S; Bosch K; Stach K; Borggrefe M; Pötzsch B; Loßnitzer D
J Crit Care; 2018 Oct; 47():41-48. PubMed ID: 29886066
[TBL] [Abstract][Full Text] [Related]
4. Aptamer loaded superparamagnetic beads for selective capturing and gentle release of activated protein C.
Hamedani NS; Happich FL; Klein EM; Rühl H; Mayer G; Oldenburg J; Müller J; Pötzsch B
Sci Rep; 2022 Apr; 12(1):7091. PubMed ID: 35490167
[TBL] [Abstract][Full Text] [Related]
5. A sensitive and facile assay for the measurement of activated protein C activity levels in vivo.
Orthner CL; Kolen B; Drohan WN
Thromb Haemost; 1993 May; 69(5):441-7. PubMed ID: 8322267
[TBL] [Abstract][Full Text] [Related]
6. Ex Vivo Modeling of the PC (Protein C) Pathway Using Endothelial Cells and Plasma: A Personalized Approach.
Schwarz N; Müller J; Yadegari H; McRae HL; Reda S; Hamedani NS; Oldenburg J; Pötzsch B; Rühl H
Arterioscler Thromb Vasc Biol; 2023 Jan; 43(1):109-119. PubMed ID: 36353988
[TBL] [Abstract][Full Text] [Related]
7. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
[TBL] [Abstract][Full Text] [Related]
8. Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000).
Gardiner C; Machin SJ; Mackie IJ
Int J Lab Hematol; 2008 Aug; 30(4):261-8. PubMed ID: 18665822
[TBL] [Abstract][Full Text] [Related]
9. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation.
Tanaka KA; Szlam F; Levy JH
Br J Haematol; 2006 Jul; 134(1):77-82. PubMed ID: 16803571
[TBL] [Abstract][Full Text] [Related]
10. Selective Modulation of the Protease Activated Protein C Using Exosite Inhibiting Aptamers.
Hamedani NS; Müller J; Tolle F; Rühl H; Pezeshkpoor B; Liphardt K; Oldenburg J; Mayer G; Pötzsch B
Nucleic Acid Ther; 2020 Oct; 30(5):276-288. PubMed ID: 32486960
[TBL] [Abstract][Full Text] [Related]
11. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions.
Mosnier LO; Yang XV; Griffin JH
J Biol Chem; 2007 Nov; 282(45):33022-33. PubMed ID: 17872949
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach.
Hamedani NS; Rühl H; Zimmermann JJ; Heiseler T; Oldenburg J; Mayer G; Pötzsch B; Müller J
Nucleic Acid Ther; 2016 Dec; 26(6):355-362. PubMed ID: 27736370
[TBL] [Abstract][Full Text] [Related]
13. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
[TBL] [Abstract][Full Text] [Related]
14. A novel protein C-factor VII chimera provides new insights into the structural requirements for cytoprotective protease-activated receptor 1 signaling.
Gleeson EM; McDonnell CJ; Soule EE; Willis Fox O; Rushe H; Rehill A; Smith OP; O'Donnell JS; Preston RJS
J Thromb Haemost; 2017 Nov; 15(11):2198-2207. PubMed ID: 28834159
[TBL] [Abstract][Full Text] [Related]
15. An aptamer-capture based chromogenic assay for thrombin.
Zhao Q; Wang X
Biosens Bioelectron; 2012 Apr; 34(1):232-7. PubMed ID: 22387038
[TBL] [Abstract][Full Text] [Related]
16. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography.
Tchaikovski SN; van Vliet HA; Thomassen MC; Bertina RM; Rosendaal FR; Sandset PM; Helmerhorst FM; Tans G; Rosing J
Thromb Haemost; 2007 Dec; 98(6):1350-6. PubMed ID: 18064335
[TBL] [Abstract][Full Text] [Related]
17. A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation.
Liaw PC; Ferrell G; Esmon CT
J Thromb Haemost; 2003 Apr; 1(4):662-70. PubMed ID: 12871399
[TBL] [Abstract][Full Text] [Related]
18. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism.
Tripodi A; Legnani C; Lemma L; Cosmi B; Palareti G; Chantarangkul V; Mannucci PM
J Thromb Thrombolysis; 2010 Aug; 30(2):215-9. PubMed ID: 20419336
[TBL] [Abstract][Full Text] [Related]
19. Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.
Rühl H; Schröder L; Müller J; Sukhitashvili S; Welz J; Kuhn WC; Oldenburg J; Rudlowski C; Pötzsch B
PLoS One; 2014; 9(8):e105007. PubMed ID: 25121606
[TBL] [Abstract][Full Text] [Related]
20. A chromogenic assay for activated protein C resistance.
Váradi K; Moritz B; Lang H; Bauer K; Preston E; Peake I; Rivard GE; Keil B; Schwarz HP
Br J Haematol; 1995 Aug; 90(4):884-91. PubMed ID: 7669667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
